Indication

PD-L1 positive squamous cell carcinoma of esophagus

PD-L1 positive squamous cell carcinoma of the esophagus is a malignant epithelial neoplasm arising from the mucosal lining of the esophagus, characterized by the histological features of squamous differentiation and the immunohistochemical expression of programmed death-ligand 1 (PD-L1). Read more about PD-L1 positive squamous cell carcinoma of esophagus

6 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common PD-L1 positive squamous cell carcinoma of esophagus therapies.

Showing 1–6 of 6 drugs

YERVOY (ipilimumab)

ANTINEOPLASTIC-CYTOTOXIC T-LYMP. ANTIGEN (CTLA-4),R-MC ANTIB·METASTATIC MALIGNANT MELANOMA·+8
BMS PRIMARYCARE

OPDIVO (nivolumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT ESOPHAGEAL NEOPLASM·+17
BMS PRIMARYCARE

KEYTRUDA (pembrolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme

TEVIMBRA (tislelizumab-jsgr)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·PD-L1 POSITIVE SQUAMOUS CELL CARCINOMA OF ESOPHAGUS·+5
BEONE MEDICINES
Filter & compare in the drug finder →Opens the drug finder with PD-L1 positive squamous cell carcinoma of esophagus preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About PD-L1 positive squamous cell carcinoma of esophagus.

PD-L1 positive squamous cell carcinoma of the esophagus is a malignant epithelial neoplasm arising from the mucosal lining of the esophagus, characterized by the histological features of squamous differentiation and the immunohistochemical expression of programmed death-ligand 1 (PD-L1).

It affects the upper gastrointestinal tract and represents a biomarker-defined subgroup of esophageal cancer commonly evaluated by tumor proportion score or combined positive score.

Pathophysiologically, the tumor's expression of PD-L1 enables immune evasion by binding to PD-1 receptors on cytotoxic T cells to inhibit host antitumor immune responses, a feature that identifies patients likely to benefit from immune checkpoint inhibitor therapy.

Clinically, it typically presents with progressive dysphagia, odynophagia, and involuntary weight loss, often demonstrating aggressive local invasion and a propensity for regional lymph node metastasis.

Personalize your experience

Follow PD-L1 positive squamous cell carcinoma of esophagus and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it